English
Русский
O'zbek
СИРОЛИМУС КАК НОВАЯ ТЕРАПЕВТИЧЕСКАЯ ОПЦИЯ ПРИ РЕЗИСТЕНТНЫХ СОСУДИСТЫХ МАЛЬФОРМАЦИЯХ У ДЕТЕЙ
Maqola haqida umumiy ma'lumotlar
Qon tomir anomaliyalari pediatriya amaliyotida uchraydigan murakkab patologiyalardan biridir. Klassik davolash usullari — skleroterapiya, jarrohlik rezektsiya, propranolol va steroidlar ko‘pincha to‘liq natija bermaydi va bemorlarning hayot sifatini sezilarli darajada cheklaydi. So‘nggi yillarda mTOR yo‘lining ingibitori bo‘lgan sirolimus murakkab va rezistent qon tomir anomaliyalarini davolashda istiqbolli dori sifatida o‘rganilmoqda.
- Wassef M, Blei F, Adams D, et al. Vascular anomalies classification: recommendations from the ISSVA. Pediatrics. 2015;136(1):e203-e214.
- Yesil S, Tanyildiz HG, Bozkurt C, et al. Single-center experience with sirolimus therapy for vascular malformations. Pediatr Hematol Oncol. 2016;33(4):219-225.
- Triana P, Dore M, Cerezo VN, et al. Sirolimus in the treatment of vascular anomalies. Eur J Pediatr Surg. 2017;27(1):86-90.
- Lackner H, Karastaneva A, Schwinger W, et al. Sirolimus for the treatment of children with various complicated vascular anomalies. Eur J Pediatr. 2015;174(12):1579-1584.
- Adams DM, Trenor CC Ⅲ, Hammill AM, et al. Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies. Pediatrics. 2016;137(2):e20153257.
- Goldenberg DC, Carvas M, Adams D, et al. Successful treatment of a complex vascular malformation with sirolimus and surgical resection. J Pediatr Hematol Oncol. 2017;39(3):e191-e195.
- Strychowsky JE, Rahbar R, O’Hare MJ, et al. Sirolimus as treatment for 19 patients with refractory cervicofacial lymphatic malformation. Laryngoscope. 2018;128(2):269-276.
- Freixo C, Ferreira V, Martins J, et al. Efficacy and safety of sirolimus in the treatment of vascular anomalies: a systematic review. J Vasc Surg. 2020;71(1):318-327.
- Durand R, et al. MRI assessment for response to sirolimus in extensive lymphatic malformations in children. AJR Am J Roentgenol. 2021;217(4):873-880.
- Maruani A, et al. Sirolimus (Rapamycin) for slow-flow malformations in children: the PERFORMUS trial. JAMA Dermatol. 2021;157(11):1289-1298.
- Durán-Romero AJ, Hernández-Rodríguez JC, Ortiz-Álvarez J, et al. Efficacy of oral sirolimus for high-flow vascular malformations in real practice. Clin Exp Dermatol. 2022;47(1):57-62.
- Saibene AM, et al. Sirolimus treatment for paediatric head and neck lymphatic malformations: a systematic review. Front Pediatr. 2023;11:10313583.
- Seront E, et al. VASE trial: sirolimus in slow-flow vascular malformations. JCI Insight. 2023;8(21):e173095.
- Ozeki M, et al. Sirolimus treatment for intractable lymphatic anomalies (SILA study). Front Med (Lausanne). 2024;11:1335469.
- Park J, Ha S, Kwon H, et al. Sirolimus for complicated vascular anomalies: a single-center 2-year experience. Ann Pediatr Surg. 2024;30(1):14-21.
- Wang J, et al. Sirolimus in the treatment of pediatric lymphatic malformations: a real-world study. Int J Pediatr Otorhinolaryngol. 2024;174:111518.
- Wang G, et al. Effectiveness and safety of sirolimus in the treatment of venous malformations. J Vasc Surg Venous Lymphat Disord. 2025;13(2):e00096-e00105.
- Nisbet R, et al. Oral sirolimus therapy for complex low-flow vascular malformations. J Vasc Surg Venous Lymphat Disord. 2025;15(2):e00096-e00105.
- Alomari AI, Fishman SJ, Burrows PE, et al. Combined embolization and sirolimus for complex vascular anomalies. Pediatr Radiol. 2019;49(12):1654-1663.
- Hammill AM, Wentzel M, Gupta A, et al. Sirolimus for maintenance therapy in pediatric vascular anomalies. Pediatr Blood Cancer. 2019;66(12):e27954.
- Shaikh R, et al. Long-term sirolimus therapy for refractory vascular malformations in children. Pediatr Surg Int. 2020;36(10):1125-1133.
- Alqahtani A, et al. Sirolimus treatment outcomes in lymphangiomas: experience from a tertiary center. World J Pediatr Surg. 2020;3:e000113.
- Kim DW, et al. Sirolimus therapy for lymphatic malformations: clinical and radiologic outcomes. Korean J Pediatr. 2021;64(5):217-224.
- Donnelly LF, et al. Imaging response patterns in children with vascular anomalies treated with sirolimus. Pediatr Radiol. 2021;51(11):1973-1981.
- Horbach SER, et al. Sirolimus for complex slow-flow vascular malformations: an international cohort study. Orphanet J Rare Dis. 2022;17:89.
- Elluru RG, et al. Role of sirolimus in airway lymphatic malformations: a multicenter review. Int J Pediatr Otorhinolaryngol. 2022;159:111229.
- Wu JK, et al. Clinical and genetic predictors of response to sirolimus in vascular malformations. Hum Genet. 2022;141(12):1959-1970.
- Perkins JA, et al. Pediatric lymphatic malformations and sirolimus: 5-year outcomes. Laryngoscope. 2023;133(4):892-900.
- Tang Y, et al. Sirolimus improves quality of life in children with cervicofacial lymphatic malformations. Eur J Pediatr. 2023;182(6):2475-2483.
- Zhang H, et al. Efficacy and safety of sirolimus in complex vascular malformations: a multicenter prospective study. Orphanet J Rare Dis. 2024;19:211.
- Xu Q, et al. Low-dose sirolimus in pediatric vascular anomalies: a prospective clinical trial. Front Pharmacol. 2024;15:1378429.
, С. ., , С. ., & , К. . (2025). СИРОЛИМУС КАК НОВАЯ ТЕРАПЕВТИЧЕСКАЯ ОПЦИЯ ПРИ РЕЗИСТЕНТНЫХ СОСУДИСТЫХ МАЛЬФОРМАЦИЯХ У ДЕТЕЙ. ALFRAGANUS, (4), 99–108. https://doi.org/
, САДЫКОВ Р.Р., et al. “СИРОЛИМУС КАК НОВАЯ ТЕРАПЕВТИЧЕСКАЯ ОПЦИЯ ПРИ РЕЗИСТЕНТНЫХ СОСУДИСТЫХ МАЛЬФОРМАЦИЯХ У ДЕТЕЙ.” Academic Research in Educational Sciences, vol. 4, no. , 2025, pp. 99–108, https://doi.org/.
, ., , ., and , . 2025. СИРОЛИМУС КАК НОВАЯ ТЕРАПЕВТИЧЕСКАЯ ОПЦИЯ ПРИ РЕЗИСТЕНТНЫХ СОСУДИСТЫХ МАЛЬФОРМАЦИЯХ У ДЕТЕЙ. Academic Research in Educational Sciences. 4(), pp.99–108.